*Pancreatic Cancer UK ‘The Optimal Care Pathway for pancreatic cancer
Pancreatic cancer is among the most lethal of all common cancers. Half of patients die within 90 days of diagnosis, largely due to the difficulty of detecting the disease in its early stages. Today, 80% of patients are diagnosed too late for potentially curative surgery.
Dxcover is developing a multi-modal detection platform to improve early diagnosis and triage of pancreatic cancer—especially in high-risk populations—enabling timely intervention and improved outcomes.
Challenges in Current Diagnosis
Today’s diagnostic pathway relies heavily on symptom presentation and imaging techniques. These approaches often miss early-stage disease, leading to late diagnoses and poor prognosis.
By combining or enhancing current biomarkers, Dxcover aims to streamline this pathway and support faster, more accurate referral for confirmatory imaging.
Why Dxcover?
Our quick, non-invasive platform is designed to fit seamlessly into clinical pathways, enabling faster triage and better outcomes.
With scalable deployment and our multiomic approach that isn’t reliant on genomic information, Dxcover brings a novel solution to one of the most urgent challenges in oncology.
EARLY DIAGNOSIS IS VITAL TO IMPROVING SURVIVAL RATES AND QUALITY OF LIFE.